Taltz (Ixekizumab) Denied by Insurance: Appeal Guide

Taltz (ixekizumab) is an IL-17A inhibitor biologic developed by Eli Lilly, FDA-approved for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It targets the same IL-17A pathway as secukinumab (Cosentyx) but has a different molecular structure, dosing schedule, and clinical trial profile. Taltz produces among the highest rates of skin clearance of any biologic in psoriasis trials and has demonstrated strong outcomes in both psoriatic and axial spondyloarthritis. Despite this clinical record, insurance denials are common and can delay access to effective treatment for months.

Why Insurance Denies Taltz

Step therapy requiring prior TNF inhibitor failure is the dominant denial reason for Taltz. Even though Taltz is FDA-approved as a first-line biologic for both psoriasis and spondyloarthritis, many commercial plans require failure of a TNF inhibitor (such as adalimumab or etanercept) before they will approve an IL-17 inhibitor. This is a formulary-driven restriction, not a clinical one. Plans favor TNF inhibitors because they have more established biosimilar competition and lower net prices for insurers.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization is required across all Taltz indications. PA criteria typically include disease severity documentation (PASI/BSA for psoriasis, joint assessments for PsA, ASDAS/BASDAI for AS), prior treatment history, and neurologist or rheumatologist attestation.

Formulary exceptions are needed when a plan has Cosentyx or another IL-17 inhibitor as the preferred agent but not Taltz. If Taltz is not on your plan's formulary, you will need to demonstrate that the covered alternative is not appropriate for you — requiring a formulary exception on top of the standard prior authorization.

For psoriasis specifically, insurers apply minimum PASI or BSA thresholds to confirm moderate-to-severe disease. Patients with significant disease on difficult-to-treat areas (scalp, face, palms, genitalia) may not meet numeric thresholds even when their quality of life is severely affected.

Pediatric use considerations can create denials for patients under 18. Taltz has FDA approval for moderate-to-severe plaque psoriasis in pediatric patients 6 years and older, but insurers may not have updated their coverage policies to reflect this pediatric approval or may apply more conservative criteria for minors.

How to Appeal a Taltz Denial

Provide objective disease severity documentation. For psoriasis, include PASI scores, BSA assessment, and DLQI scores. A PASI of 12 or above or BSA of 10% or more generally confirms moderate-to-severe classification. For difficult-to-treat areas, ask your dermatologist to document the specific location and functional or quality-of-life impact (face, hands, feet, genitalia disproportionately impair function and quality of life).

Document prior systemic treatment failure. Your appeal should clearly list every conventional and biologic treatment you have tried for psoriasis or your spondyloarthritis, including dates, doses, and reasons for stopping. For psoriasis, this should include at least one topical therapy failure and at least one conventional systemic therapy. For AS/nr-axSpA, NSAID failure is typically the first required step before any biologic.

If a TNF inhibitor was tried and failed: Provide clinical records and disease activity scores from that treatment period. Document whether the failure was primary (never responded) or secondary (lost response over time) — both are legitimate grounds for trying a different class like IL-17.

If a TNF inhibitor was never tried and step therapy is required: Your physician should write a letter explaining why proceeding directly to IL-17 inhibition is appropriate. Clinical reasons might include: a disease profile with predominantly skin involvement (where IL-17 inhibitors have superior evidence), contraindication to TNF inhibitors, patient preference based on shared decision-making, or prior treatment in another class that suggests better fit for IL-17 inhibition.

Challenge the step therapy restriction with state law. Many states require insurers to grant step therapy exceptions when a physician certifies the required first-line drug is clinically inferior, contraindicated, or previously failed. File a formal step therapy exception in addition to your standard appeal.

Request peer-to-peer review. Have your dermatologist or rheumatologist speak directly with the insurer's clinical reviewer. The clinical argument for IL-17 inhibition as first-line in high-burden psoriasis or spondyloarthritis is well-supported by published evidence and is often more persuasive in conversation than in writing.

Patient Assistance Programs

Eli Lilly offers the Lilly Cares Foundation Patient Assistance Program, which provides free Taltz for qualifying uninsured or underinsured patients. Copay assistance is available for commercially insured patients with high out-of-pocket costs. Visit taltz.com or call 1-833-4TALTZ (1-833-482-5897).

Taltz is dosed monthly after initial loading doses, with a list price of approximately $60,000–$75,000 per year, making patient assistance programs critical for access while an appeal is pending.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?